论文部分内容阅读
目的研究尿激酶型纤溶酶原激活物受体(uPAR)在下咽癌组织中的表达及其临床意义。方法应用免疫组织化学SABC法检测下咽癌患者50例(A组)和对照组10例(B组)uPAR蛋白表达,分析其与下咽癌临床病理参数及颈淋巴结转移的关系。结果A组uPAR表达阳性率68%,明显高于B组的10%(P<0.01)。uPAR的表达与病理分级、淋巴结转移相关(P<0.01),而与临床分期、年龄、性别无关(P>0.05)。结论uPAR蛋白在下咽癌中阳性表达明显上调,且与病理分级、淋巴结转移相关,可作为下咽癌诊断和预后的参考指标之一。
Objective To study the expression of urokinase-type plasminogen activator receptor (uPAR) in hypopharyngeal carcinoma and its clinical significance. Methods Immunohistochemical SABC method was used to detect the expression of uPAR in 50 patients with hypopharyngeal carcinoma (A group) and 10 patients in control group (B group). The relationship between them and clinicopathological parameters and lymph node metastasis of hypopharyngeal carcinoma was analyzed. Results The positive rate of uPAR expression in group A was 68%, which was significantly higher than that in group B (P <0.01). The expression of uPAR was correlated with pathological grade and lymph node metastasis (P <0.01), but not with clinical stage, age and gender (P> 0.05). Conclusion The positive expression of uPAR protein in hypopharyngeal carcinoma was significantly up-regulated, and it was correlated with pathological grade and lymph node metastasis, which could be used as a reference index for the diagnosis and prognosis of hypopharyngeal carcinoma.